Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Piero Barbanti; Gabriella Egeo; Stefania Proietti; Florindo d’Onofrio; Cinzia Aurilia; Cinzia Finocchi; Laura Di Clemente; Maurizio Zucco; Alberto Doretti; Stefano Messina; Massimo Autunno; Angelo Ranieri; Antonio Carnevale; Bruno Colombo; Massimo Filippi; Miriam Tasillo; Steno Rinalduzzi; Pietro Querzani; Giuliano Sette; Lorenzo Forino; Francesco Zoroddu; Micaela Robotti; Alessandro Valenza; Cecilia Camarda; L. Borrello; Marco Aguggia; Giovanna Viticchi; Carlo Tomino; Giulia Fiorentini; Bianca Orlando; Stefano Bonassi; Paola Torelli

doi:10.1007/s40120-024-00591-z

Shared by

Massimo Filippi

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Article 2024 en

Authors

PB
Piero Barbanti
GE
Gabriella Egeo
SP
Stefania Proietti

Abstract

1 min read

This RWE study documents that long-term fremanezumab treatment is highly effective and remarkably well tolerated in subjects with HFEM or CM with multiple (> 3) therapeutic failures, even in the presence of concomitant medication overuse, psychiatric comorbidities, or both. The effectiveness-to-tolerability ratio appears to be better in RWE than in RCTs.

Discussion(0)

No comments yet. Be the first to comment.

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Abstract

Discussion(0)

Related publications

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures. The multicenter, prospective, real-life FRIEND2 study.

Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Related publications

Preprint2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures. The multicenter, prospective, real-life FRIEND2 study.
Preprint2023

Article2021
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Article2021

Article2024
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study
Article2024

Article2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Article2023

Corrigendum2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Corrigendum2024